PMID: 237 CortesJCesconDWRugoHSNoweckiZImSAYusofMMet al

Critical Contraindication Screening: Specific questions designed to identify absolute contraindications requiring immediate exclusion from GLP-1 therapy: Personal history of medullary thyroid carcinoma (MTC), a rare thyroid cancer type Family history of MTC in first-degree relatives (parents, siblings, children) Multiple endocrine neoplasia syndrome type 2 (MEN 2) diagnosis or known family history Current pregnancy status, recent pregnancy within past 3 months, breastfeeding, or plans to become pregnant during treatment period History of severe hypersensitivity reactions or anaphylaxis to semaglutide, tirzepatide, or related GLP-1 medications Active pancreatitis or history of recurrent pancreatitis episodes Severe kidney disease with estimated glomerular filtration rate (eGFR) below 30 mL/min/1.73m History of diabetic retinopathy requiring active treatment or recent progression Severe gastrointestinal disease including active gastroparesis significantly impairing stomach emptying History of suicidal ideation, suicide attempts, or severe depression requiring intensive psychiatric care Age under 18 years (insufficient pediatric safety data for most compounded formulations) Step 2: Licensed Medical Provider Review and Clinical Determination Once comprehensive assessment submission occurs, information enters clinical review queue where licensed healthcare providers evaluate eligibility: Provider Credentialing Through OpenLoop Health: All reviewing clinicians maintain active unrestricted state medical licenses and operate through OpenLoop Health, a multi-state telehealth medical provider network

Then a steady decline begins
Are follow-ups and dose adjustments built in
Choose Bpc-157 When Facing Tendon injuries including tennis elbow, golfers elbow, Achilles tendonitis, patellar tendinopathy, and rotator cuff issues Ligament damage especially partial tears and sprains Gastrointestinal problems including ulcers, IBD, IBS, gastritis, and leaky gut Need to protect tissues from corticosteroid damage Nerve tissue protection and neuroprotection applications Single localized injury requiring targeted repair Bpc-157 uniquely prevents corticosteroid damage to tendons, directly upregulates growth hormone receptors on tendon fibroblasts, and can be taken orally with maintained bioavailability for gut issues
People who are already on thyroid medications will need more frequent monitoring of their thyroid levels and possible adjustments of medications because of absorption changes in the stomach and weight loss